Unoprostone 

Unoprostone, a prostaglandin F2α analogs (PGAs), activates BK channels to reduce oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and is used topically for glaucoma or ocular hypertension^[1].

Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H₂O₂ treatment) protects against H₂O₂-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations^[1].
Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation^[1].
Unoprostone has prostaglandin F_2α receptors (FP) binding affinity with a K_i of 3.86 μM^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Unoprostone (0.06%, 0.12%; topical instillation; 3 µl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

382.53

C₂₂H₃₈O₅

120373-36-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tsuruma K, et al. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytoticdysfunction, by activating BK channels. Mol Vis. 2011;17:3556-65. Epub 2011 Dec 30.  [Content Brief]

  [2]. Kelly CR, et al. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and otheranalogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmacol Exp Ther. 2003 Jan;304(1):238-45.  [Content Brief]

  [3]. Ota T, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.  [Content Brief]